Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2013-2020

  Kumar, Rupesh ^a   Madhumathi, Bhavani Shankar ^a   Nagaraja, Valakunja ^a,b  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; BACTERIAL ENZYME; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GATIFLOXACIN; HOLOENZYME; MOXIFLOXACIN; OFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BINDING AFFINITY; CELL KILLING; CONTROLLED STUDY; DNA CLEAVAGE; DRUG DNA BINDING; ENZYME INHIBITION; ESCHERICHIA COLI; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; MYCOBACTERIUM TUBERCULOSIS; QUINOLONES;

EID: 84896931441     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01958-13     Document Type: Article

References (58)

1. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. 1976. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. U. S. A. 73:3872-3876. http://dx.doi.org/10.1073/pnas.73.11.3872.
2. Wang JC. 1996. DNA topoisomerases. Annu. Rev. Biochem. 65:635-692. http://dx.doi.org/10.1146/annurev.bi.65.070196.003223. (Pubitemid 26250622)
3. Champoux JJ. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413. http://dx.doi.org/10.1146/annurev. biochem.70.1.369. (Pubitemid 32662215)
4. Berger JM, Gamblin SJ, Harrison SC, Wang JC. 1996. Structure and mechanism of DNA topoisomerase II. Nature 379:225-232. http://dx.doi.org/10. 1038/379225a0. (Pubitemid 26025206)
5. Maxwell A. 1993. The interaction between coumarin drugs and DNA gyrase. Mol. Microbiol. 9:681-686. http://dx.doi.org/10.1111/j.1365-2958.1993.tb01728.x. (Pubitemid 23253494)
6. Goetschi E, Angehrn P, Gmuender H, Hebeisen P, Link H, Masciadri R, Nielsen J. 1993. Cyclothialidine and its congeners: a new class of DNA gyrase inhibitors. Pharmacol. Ther. 60:367-380. http://dx.doi.org/10.1016/0163-7258(93) 90017-8. (Pubitemid 24117386)
7. Drlica K. 1999. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 2:504-508. http://dx.doi.org/10.1016/S1369-5274(99)00008-9. (Pubitemid 29477177)
8. Bahassi EM, O'Dea MH, Allali N, Messens J, Gellert M, Couturier M. 1999. Interactions of CcdB with DNA gyrase: inactivation of GyrA, poisoning of the gyrase-DNA complex, and the antidote action of CcdA. J. Biol. Chem. 274:10936-10944.
9. Heddle JG, Blance SJ, Zamble DB, Hollfelder F, Miller DA, Wentzell LM, Walsh CT, Maxwell A. 2001. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. J. Mol. Biol. 307:1223-1234. http://dx.doi.org/10.1006/jmbi.2001.4562. (Pubitemid 33027635)
10. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940. http://dx.doi.org/10. 1038/nature09197.
11. Flatman RH, Howells AJ, Heide L, Fiedler HP, Maxwell A. 2005. Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action. Antimicrob. Agents Chemother. 49:1093-1100. http://dx.doi.org/10.1128/AAC.49.3. 1093-1100.2005. (Pubitemid 40327729)
12. Hashimi SM, Wall MK, Smith AB, Maxwell A, Birch RG. 2007. The phytotoxin albicidin is a novel inhibitor of DNA gyrase. Antimicrob. Agents Chemother. 51:181-187. http://dx.doi.org/10.1128/AAC.00918-06. (Pubitemid 46047704)
13. Karkare S, Chung TT, Collin F, Mitchenall LA, McKay AR, Greive SJ, Meyer JJ, Lall N, Maxwell A. 2012. The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action. J. Biol. Chem. 288:5149-5156. http://dx.doi.org/10.1074/jbc.M112.419069.
14. McCullough JE, Muller MT, Howells AJ, Maxwell A, O'Sullivan J, Summerill RS, Parker WL, Wells JS, Bonner DP, Fernandes PB. 1993. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase. J. Antibiot. (Tokyo) 46:526-530. http://dx.doi.org/10.7164/antibiotics.46.526. (Pubitemid 23127316)
15. Tari LW, Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Nix J, Finn J. 2012. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). I. Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity. Bioorg. Med. Chem. Lett. 23:1529-1536. http://dx.doi.org/10.1016/j.bmcl.2012.11.032.
16. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392. http://dx.doi.org/10.1128/AAC. 01617-06. (Pubitemid 351170804)
17. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. http://dx.doi.org/10.1016/j.cell.2007.06.049. (Pubitemid 47332566)
18. Oliphant CM, Green GM. 2002. Quinolones: a comprehensive review. Am. Fam. Physician 65:455-464. (Pubitemid 34174022)
19. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662. http://dx.doi.org/10.1164/rccm.167.4.603.
20. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288. http://dx.doi.org/10.1128/AAC.48.4.1281-1288.2004. (Pubitemid 38405482)
21. Manjunatha UH, Dalal M, Chatterji M, Radha DR, Visweswariah SS, Nagaraja V. 2002. Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase. Nucleic Acids Res. 30:2144-2153. http://dx.doi.org/10.1093/nar/30. 10.2144. (Pubitemid 34567935)
22. Shen LL, Pernet AG. 1985. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc. Natl. Acad. Sci. U. S. A. 82:307-311. http://dx.doi.org/10.1073/pnas.82.2.307. (Pubitemid 15128258)
23. Shen LL. 2001. Quinolone interactions with DNA and DNA gyrase. Methods Mol. Biol. 95:171-184.
24. Shen LL, Kohlbrenner WE, Weigl D, Baranowski J. 1989. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J. Biol. Chem. 264:2973-2978. (Pubitemid 19057797)
25. Shen LL, Mitscher LA, Sharma PN, O'Donnell TJ, Chu DW, Cooper CS, Rosen T, Pernet AG. 1989. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28:3886-3894. http://dx.doi.org/10.1021/bi00435a039. (Pubitemid 19125438)
26. Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S. 1993. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 37:839-845. http://dx.doi.org/10.1128/AAC.37.4. 839. (Pubitemid 23096888)
27. Heddle J, Maxwell A. 2002. Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob. Agents Chemother. 46:1805-1815. http://dx.doi.org/10.1128/ AAC.46.6.1805-1815.2002. (Pubitemid 34535201)
28. Kumar R, Riley JE, Parry D, Bates AD, Nagaraja V. 2012. Binding of two DNA molecules by type II topoisomerases for decatenation. Nucleic Acids Res. 40:10904-10915. http://dx.doi.org/10.1093/nar/gks843.
29. Maxwell A, Howells AJ. 1999. Overexpression and purification of bacterial DNA gyrase. Methods Mol. Biol. 94:135-144.
30. Peng H, Marians KJ. 1993. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J. Biol. Chem. 268:24481-24490. (Pubitemid 23335445)
31. Banerjee SK, Bhatt K, Misra P, Chakraborti PK. 2000. Involvement of a natural transport system in the process of efflux-mediated drug resistance in Mycobacterium smegmatis. Mol. Gen. Genet. 262:949-956. http://dx.doi.org/10. 1007/PL00008663. (Pubitemid 30072124)
32. Favicchio R, Dragan AI, Kneale GG, Read CM. 2009. Fluorescence spectroscopy and anisotropy in the analysis of DNA-protein interactions. Methods Mol. Biol. 543:589-611. http://dx.doi.org/10.1007/978-1-60327-015-1-35.
33. Bougie I, Charpentier S, Bisaillon M. 2003. Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase. J. Biol. Chem. 278:3868-3875. http://dx.doi.org/10.1074/jbc.M209785200. (Pubitemid 36801116)
34. Hooper DC. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32(Suppl 1):S9 -S15.
35. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. 1994. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J. Infect. Dis. 170:479-483. http://dx.doi.org/10.1093/infdis/170.2.479. (Pubitemid 24226388)
36. Grosset JH. 1992. Treatment of tuberculosis in HIV infection. Tuberc. Lung Dis. 73:378-383. http://dx.doi.org/10.1016/0962-8479(92)90044-K.
37. Tsukamura M, Nakamura E, Yoshii S, Amano H. 1985. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am. Rev. Respir. Dis. 131:352-356. (Pubitemid 15133592)
38. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. 1998. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984. (Pubitemid 28501236)
39. Corbett KD, Berger JM. 2004. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct. 33:95-118. http://dx.doi.org/10.1146/annurev.biophys.33.110502.140357. (Pubitemid 38829953)
40. Noble CG, Barnard FM, Maxwell A. 2003. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex. Antimicrob. Agents Chemother. 47:854-862. http://dx.doi.org/10.1128/AAC.47.3.854-862.2003. (Pubitemid 36254206)
41. Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR. 2009. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 16:667-669. http://dx.doi.org/10.1038/nsmb.1604.
42. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD. 2010. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 17:1152-1153. http://dx.doi.org/10.1038/nsmb.1892.
43. Yoshida H, Bogaki M, Nakamura M, Nakamura S. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272. http://dx.doi.org/10.1128/AAC.34.6. 1271. (Pubitemid 20177394)
44. Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. 2004. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601. http://dx.doi.org/10.1128/AAC.48.2. 596-601.2004. (Pubitemid 38141721)
45. Critchlow SE, Maxwell A. 1996. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry 35:7387-7393. http://dx.doi.org/10.1021/bi9603175.
46. Palu G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. 1992. Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. U. S. A. 89:9671-9675. http://dx.doi.org/10.1073/pnas.89.20.9671.
47. Aldred KJ, McPherson SA, Turnbough CL, Jr, Kerns RJ, Osheroff N. 2013. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 41:4628-4639. http://dx.doi.org/10.1093/nar/gkt124.
48. Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL, Jr, Osheroff N. 2012. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry 51:370-381. http://dx.doi.org/10.1021/bi2013905.
49. Kampranis SC, Maxwell A. 1998. The DNA gyrase-quinolone complex: ATP hydrolysis and the mechanism of DNA cleavage. J. Biol. Chem. 273:22615-22626. (Pubitemid 28399831)
50. Sengupta S, Nagaraja V. 2008. Inhibition of DNA gyrase activity by Mycobacterium smegmatis MurI. FEMS Microbiol. Lett. 279:40-47. http://dx.doi.org/10.1111/j.1574-6968.2007.01005.x. (Pubitemid 350308546)
51. Sengupta S, Nagaraja V. 2008. YacG from Escherichia coli is a specific endogenous inhibitor of DNA gyrase. Nucleic Acids Res. 36:4310-4316. http://dx.doi.org/10.1093/nar/gkn355.
52. Tran JH, Jacoby GA, Hooper DC. 2005. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 49:118-125. http://dx.doi.org/10.1128/AAC.49.1.118-125.2005. (Pubitemid 40065781)
53. Eaves DJ, Randall L, Gray DT, Buckley A, Woodward MJ, White AP, Piddock LJ. 2004. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica. Antimicrob. Agents Chemother. 48:4012-4015. http://dx.doi.org/10.1128/AAC.48.10.4012-4015.2004. (Pubitemid 39304637)
54. Nakamura S, Nakamura M, Kojima T, Yoshida H. 1989. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob. Agents Chemother. 33:254-255. http://dx.doi.org/10.1128/AAC.33.2.254. (Pubitemid 19053872)
55. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 67:819-831. http://dx.doi.org/10. 1093/jac/dkr566.
56. Zhou J, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, Domagala J, Musser JM, Drlica K. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525. http://dx.doi.org/10.1086/315708. (Pubitemid 30651049)
57. Piton J, Petrella S, Delarue M, Andre-Leroux G, Jarlier V, Aubry A, Mayer C. 2010. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 5:e12245. http://dx.doi.org/10. 1371/journal.pone.0012245.
58. Sissi C, Perdona E, Domenici E, Feriani A, Howells AJ, Maxwell A, Palumbo M. 2001. Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions. J. Mol. Biol. 311:195-203. http://dx.doi.org/10. 1006/jmbi.2001.4838. (Pubitemid 32735324)